Our Pricing

Buy Wegovy In Stock UK - All Doses Available Now

When you need to buy Wegovy in stock UK with guaranteed availability across all doses, Cured Pharmacy offers transparent upfront pricing from £79.00, UK-registered prescribers, and discreet next-day delivery. Our clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), has helped thousands of UK patients access genuine semaglutide weight loss treatment through our streamlined online consultation process that takes under three minutes.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1 in your body. This medication works by slowing gastric emptying, reducing appetite signals in the brain, and improving how your body regulates blood sugar levels [1]. Unlike stimulant-based weight loss medications, semaglutide addresses the underlying hormonal mechanisms that control hunger and satiety.

In the landmark STEP 1 clinical trial, participants using Wegovy alongside lifestyle modifications achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [1]. These results represent one of the most significant advances in pharmacological weight management approved by the MHRA for UK patients.

The medication is administered as a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm. Your UK prescriber will determine your starting dose based on your medical history, current medications, and weight loss goals during your clinical assessment.

Wegovy Dosing Schedule and All Available Strengths

Wegovy follows a gradual dose escalation protocol designed to minimise gastrointestinal side effects whilst optimising weight loss efficacy. At Cured Pharmacy, we maintain stock of all five licensed doses to ensure uninterrupted treatment progression for our patients.

The standard titration schedule begins with 0.25mg weekly for four weeks, increasing to 0.5mg for four weeks, then 1mg for four weeks, followed by 1.7mg for four weeks, before reaching the maintenance dose of 2.4mg weekly [2]. This gradual approach allows your body to adapt to the medication whilst your prescriber monitors your response and tolerability.

Each pre-filled pen delivers four doses at the prescribed strength, and your UK prescriber will indicate on your prescription when to progress to the next dose level. Some patients may require a slower titration schedule based on individual tolerance, which your clinical team will discuss during follow-up assessments.

Understanding the Maintenance Phase

Most patients reach the 2.4mg maintenance dose after approximately 16-20 weeks of treatment. Clinical trials demonstrate that continued use at this maintenance dose produces sustained weight loss over 68 weeks, with many patients experiencing progressive improvements in metabolic health markers including HbA1c, blood pressure, and lipid profiles [1][2].

Why Wegovy Stock Availability Matters

Wegovy experienced significant supply constraints across UK pharmacies throughout 2023 and early 2024, leaving many patients unable to access their prescribed doses. These shortages disrupted treatment continuity, potentially affecting weight loss outcomes and metabolic improvements achieved during earlier treatment phases.

At Cured Pharmacy, we've established reliable supply chains with UK-licensed wholesalers to maintain consistent stock across all Wegovy doses. Our pharmaceutical team monitors inventory levels daily and communicates proactively with patients about their upcoming prescription requirements, ensuring you never face unexpected treatment interruptions.

Continuous treatment is particularly important with semaglutide therapy because interruptions longer than two weeks may require restarting the titration schedule from a lower dose to minimise side effects [2]. Our guaranteed stock availability protects your treatment progress and helps you maintain the metabolic benefits you've worked to achieve.

Prescription Continuity and Automatic Reminders

Our clinical team provides prescription reminders seven days before your medication is due to run out, allowing sufficient time for prescriber review and next-day delivery. This proactive approach ensures seamless treatment continuation without the stress of last-minute prescription requests or stock concerns.

Wegovy vs Alternative Weight Loss Treatments

Several prescription weight loss medications are licensed in the UK, each with distinct mechanisms, efficacy profiles, and suitability for different patient populations. Understanding these differences helps you and your prescriber select the most appropriate treatment for your circumstances.

Semaglutide-based treatments like Wegovy work exclusively through GLP-1 receptor activation, whilst newer dual-agonist medications target both GLP-1 and GIP receptors. Older treatments such as orlistat work through fat absorption inhibition rather than appetite regulation, producing different side effect profiles and generally lower weight loss outcomes [3].

Your UK prescriber will consider your BMI, previous weight loss attempts, existing medical conditions, current medications, and personal preferences when recommending treatment. All prescription weight loss medications require ongoing lifestyle modifications including reduced calorie intake and increased physical activity to achieve optimal results [4].

Clinical Eligibility and UK Prescribing Criteria

Wegovy is licensed in the UK for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [2]. These MHRA-approved criteria ensure the medication is prescribed to patients most likely to benefit whilst minimising inappropriate use.

During your online consultation at Cured Pharmacy, our UK-registered prescribers assess your medical history, current medications, previous weight loss attempts, and any contraindications to semaglutide therapy. Certain conditions including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease may preclude Wegovy use.

The consultation process takes under three minutes to complete and includes questions about your weight history, eating patterns, physical activity levels, and treatment expectations. This information allows your prescriber to determine whether Wegovy is clinically appropriate and safe for you, with decisions typically provided within hours of submission.

Ongoing Monitoring and Prescriber Support

NICE guidelines recommend regular monitoring of weight loss progress, side effects, and metabolic parameters throughout Wegovy treatment [4]. Our clinical team conducts follow-up assessments at 12-week intervals to evaluate treatment response, adjust dosing if needed, and provide ongoing support for lifestyle modifications that enhance medication efficacy.

Common Side Effects and Management Strategies

Gastrointestinal side effects are the most frequently reported adverse events with Wegovy, particularly during dose escalation phases. Nausea affects approximately 44% of patients, whilst vomiting, diarrhoea, and constipation occur in 24%, 30%, and 24% of users respectively [1]. These effects typically diminish over several weeks as your body adapts to each new dose level.

Practical management strategies include eating smaller, more frequent meals, avoiding high-fat foods that delay gastric emptying further, staying well-hydrated, and timing your injection for evenings if nausea is problematic during daytime hours. Your prescriber may recommend temporarily remaining at a lower dose if side effects are significantly impacting your quality of life.

Serious adverse events are rare but include potential risks of pancreatitis, gallbladder disease, and hypoglycaemia in patients taking concurrent diabetes medications [2]. Our clinical team provides detailed safety information during your consultation and maintains regular contact throughout your treatment to identify any concerning symptoms requiring medical attention. You should contact NHS 111 or your GP immediately if you experience severe abdominal pain, persistent vomiting, or signs of allergic reaction.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Novo Nordisk. (2023). Wegovy 2.4 mg Solution for Injection in Pre-filled Pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799
3. Torgerson, J. S., et al. (2004). XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155
4. National Institute for Health and Care Excellence. (2023). Semaglutide for Managing Overweight and Obesity: Technology Appraisal Guidance [TA875]. https://www.nice.org.uk/guidance/ta875

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine and results may vary between individuals.